Indeed, significant anti-tumor efficacy has previously been reported in breast cancer xenograft models using VEGFR-1-neutralizing antibodies, targeting both tumor and stromal cells, and improving the response to chemotherapy [26,27]. This evidence concerns the gene FLT1 and breast cancer.